By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Les Cardoulines HT1, Allée de la Nertière,

Sophia Antipolis   Valbonne   06560   France
Phone: 33-0-497-218-300 Fax: 33-0-493-641-580


Company News
TxCell To Present Its Cellular Immunotherapy Developments At Leading Investor Conferences 9/28/2015 10:59:15 AM
TxCell: Financial Results For The First Half Of 2015 9/22/2015 2:22:56 PM
TxCell Granted U.S. Orphan Drug Designation For Col-Treg In The Treatment Of Chronic Non-Infectious Uveitis 9/14/2015 9:25:17 AM
TxCell Announces Peer-Reviewed Publication Of Preclinical Efficacy Results For Col-Treg In Autoimmune Uveitis In A Leading Ophthalmology Journal 9/8/2015 4:21:31 PM
TxCell Consortium Granted EUR 1.28 Million For TRUST Project On Process And Clinical Development Of Col-Treg For Autoimmune Uveitis Treatment 8/24/2015 2:33:02 PM
TxCell: Financial Information For The First Half Of 2015 8/4/2015 10:48:30 AM
Orgenesis Subsidiary MaSTherCell To Manufacture TxCell's Lead Product Ovasave For Multi-National Phase 2b Trial 7/30/2015 12:09:26 PM
TxCell Appoints MaSTherCell For The Manufacturing Of Lead Product Ovasave From Q2 2016 7/29/2015 9:07:18 AM
TxCell Receives Fast Track Designation From FDA For Ovasave 7/27/2015 10:27:05 AM
EXCLUSIVE: Juno Therapeutics (JUNO)/Celgene (CELG) Deal "Great Validation" for Cellular Therapy, TxCell CEO Tells BioSpace (DHX) 7/1/2015 10:56:17 AM